Taipei Medical University Institutional Repository:Item 987654321/6472
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 45073/58249 (77%)
Visitors : 2390045      Online Users : 161
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/6472


    题名: Ambroxol緩釋錠之製造及其特性研究
    PREPARATION AND CHARACTERIZATIONS OF AMBROXOL SR TABLET
    作者: 許天賜
    Hsu Tien-Tzu
    贡献者: 藥學研究所
    关键词: ambroxol
    緩釋劑型
    熱融造粒法
    ambroxol
    sustained release
    melt-coating granulation
    日期: 2003
    上传时间: 2009-09-11 16:56:31 (UTC+8)
    摘要: 本論文之研究目的乃在於發展以口服方式投與一天一次的緩釋型Ambroxol錠劑。藉由熱融造粒技術可以得到一最佳化的藥物釋出速率且具有24小時的持續性釋放藥物之錠片，商品名定為”安疏痰 緩釋錠片” （Amsolvon SR Tablet），同時評估其錠片之物化性質，包括重量差異試驗、含量均一度試驗、硬度試驗、粉碎度試驗及溶離度試驗等。
    體外溶離試驗結果顯示熱融顆粒大小與壓錠速率並無明顯改變藥物的釋放速率與釋放總量，然而錠片的硬度卻有所不同。低壓錠速率與大顆粒所壓製得到的錠片錠片硬度較高，此乃因為錠片賦形劑具有塑性形變之特質。基於藥物溶離不受顆粒大小所影響與高產率的考量下，最後選擇顆粒規格在420 mm （以40號篩網過篩）以下之Ambroxol-Compritol 888之熱融顆粒與其他錠片組成物質混合後，以20 rpm的壓錠速率製造”安疏痰 緩釋錠片”；此錠片進一步與國外市售Ambroxol緩釋膠囊（PR-ABX Capsules、Mucosolvan Capsules）進行體外溶離試驗比對。結果顯示”安疏痰 緩釋錠片”與PR-ABX Capsules有較佳的溶離相似度。而”安疏痰 緩釋錠片”的藥物釋放機制屬於Higuchi滲透模式，亦即藥物釋放速率與溶離時間的平方根成正比關係。長期與加速安定性試驗顯示”安疏痰 緩釋錠片”之有效期限至少可達4年。
    選擇四位健康成年男性受試者進行”安疏痰 緩釋錠片”之先期性藥物動力學研究，採用多重劑量口服方式投與，結果顯示其具有持續釋放ambroxol達24小時之能力。於穩定血中濃度狀態之相關藥動學參數平均值與標準偏差值如下:AUC0-24為1559.6±149.4 ng/mL·hr、Cmax為104.63±6.34 ng/mL、Cmin為38.83±13.86 ng/mL、Cav為64.98±6.22 ng/mL、fluctuation為1.03±0.30、AUMC0-24為16246±1784 ng/mL·hr2、MRT0-24為10.41±0.46 hr、Tmax為7.50±1.29 hr、Kel為0.0673±0.0091 hr-1、T1/2為10.46±1.53 hr、CL/F為48.40±4.33 L/hr、Vd/F為735.45±162.44 L.
    “安疏痰 緩釋錠片”已核准開始進行臨床藥效評估，預期此一製劑在未來將可提供更安全穏定的藥物療效，同時增加病患的依順性。
    The purpose of this study was to develop a sustained release tablet of ambroxol that to be taken once daily. The optimized ambroxol sustained release tablet, Amsolvon SR tablet as trade name, was prepared via a melt-coating granulation technique and its functionality was characterized based on the following tests: weight variation, content uniformity, hardness, friability and dissolution tests.
    In vitro dissolution studies show that the drug release rate and amount are not affected by particle size of ambroxol-Compritol 888 melted granules and tabletting speeds. But the hardness of ambroxol SR tablets is influenced by particle sizes and tabletting speeds. Low tabletting speed and large particle size may produce more compact tablets; this can be attributed to the plastic deformation characteristic of the tablet excipients.
    Finally the particle size of <420 mm of ambroxol-Compritol 888 melted particles were selected in terms of higher production yield. The selected melted particles were mixed thoroughly and tabletted at 20 rpm to obtain Amsolvon SR tablets. The dissolution profile of Amsolvon SR tablets was more similar with PR-ABX capsules than Mucosolvan capsules in all three dissolution media. The drug release mechanism of ambroxol from Amsolvon SR tablets can be described by Higuchi diffusion model. The long-term and accelerated stability tests both showed that Amsolvon SR tablet was stable and its tentative shelf life was 4 years at least.
    Pharmacokinetic pilot study in four healthy male human subject after oral administration with multiple doses of Amsolvon SR tablets show that the formulation was successful in providing slow release of ambroxol and has mean±SD AUC0-24 of 1559.6±149.4 ng/mL·hr, Cmax of 104.63±6.34 ng/mL, Cmin of 38.83±13.86 ng/mL, Cav of 64.98±6.22 ng/mL, fluctuation of 1.03±0.30, AUMC0-24 of 16246±1784 ng/mL·hr2, MRT0-24 of 10.41±0.46 hr, Tmax of 7.50±1.29 hr, Kel of 0.0673±0.0091 hr-1, T1/2 of 10.46±1.53 hr, CL/F of 48.40±4.33 L/hr, and Vd/F of 735.45±162.44 L.
    The efficacy and safety of this ambroxol SR tablet (Amsolvon SR tablet) dosage form are currently being evaluated in clinical trials; it may be expected to provide optimum therapeutic efficacy and improve patient’s compliance in the future.
    数据类型: thesis
    显示于类别:[School of Pharmacy] Dissertation/Thesis

    文件中的档案:

    档案 描述 大小格式浏览次数
    摘要.doc31KbMicrosoft Word266检视/开启
    摘要.pdf483KbAdobe PDF385检视/开启
    摘要.ppt113KbMicrosoft Powerpoint138检视/开启
    摘要.ps522KbPostscript107检视/开启


    在TMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈